BIND

Overview

We adopt transformative therapeutic approaches to develop non-invasive and first-in-class intervention strategies for patients with rare repeat-expansion diseases, specifically for polygutamine disorders (including Huntington's Disease) and amyotrophic lateral sclerosis/frontal temporal dementia. This technology has been licensed by CUHK academic-led start-up Rare Power Limited.

Commercialisation opportunities

Product/Service Distribution

Problem addressed

In the current market, no drugs are availble for treatment or cure for rare repeat-expansion diseases. For example, drugs for Huntington's Disease and amyotrophic lateral sclerosis/frontal temporal dementia are mainly symptom-relieving.

Innovation

A non-invasive medication (intranasal)
First-in-class

Key impact

Better brain uptake via the intranasal route
Cure the rare repeat expansion disease patients

Application

- BIND: Spinocerebellar ataxia type 3 (SCA3), Huntington's Disease(HD), C9ORF72ALS/FTD patients - BCH001: PolyQSCAs/HD patients

Patent

Peptidylic inhibitor targeting CAG-repeat RNA toxicity in polyglutamine diseases. U.S. Patent US-2017-0233442-A1, August 17, 2017
Peptidylic inhibitors targeting C9ORF72 hexanucleotide repeat-mediated neurodegeneration. U.S. Patent US-2018-0214515-A1, August 2, 2018
Small molecule inhibitors targeting CAG-repeat RNA toxicity in polyglutamine diseases. U.S. Patent US 10,143,666, Dec 4, 2018
miRNA dysregulation correction as a stratrgy to treat Hungtinton's Disease. Provisional Patent No.: US 63/384,243 filled on 18 November 2022

Website

The Chinese University of Hong Kong (CUHK)

Founded in 1963, The Chinese University of Hong Kong (CUHK) is a forward-looking comprehensive research university with a global vision and a mission to combine tradition with modernity, and to bring together China and the West. CUHK teachers and students hail from all around the world. Four Nobel laureates are associated with the university, and it is the only tertiary institution in Hong Kong with recipients of the Nobel Prize, Turing Award, Fields Medal and Veblen Prize sitting as faculty in residence. CUHK graduates are connected worldwide through an extensive alumni network. CUHK undertakes a wide range of research programmes in many subject areas, and strives to provide scope for all academic staff to undertake consultancy and collaborative projects with industry.

Enquiry